Seres president and chief executive Eric Shaff
April 6, 2022 01:41 PM EDT
R&D

Seres qui­et­ly dis­clos­es it has once again al­tered plans in ul­cer­a­tive col­i­tis

Kyle LaHucik

Senior Reporter

A month af­ter an­oth­er set­back in its plans to treat ul­cer­a­tive col­i­tis, Seres Ther­a­peu­tics qui­et­ly dis­closed it will not move for­ward with a Phase Ib …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times